Becton Dickinson and Co  

(Public, NYSE:BDX)   Watch this stock  
Find more results for BDX
+1.17 (0.78%)
Nov 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 150.10 - 152.20
52 week 128.87 - 154.98
Open 150.84
Vol / Avg. 645,674.00/876,011.00
Mkt cap 31.64B
P/E 44.50
Div/yield 0.66/1.74
EPS 3.40
Shares 210.74M
Beta 0.99
Inst. own 87%
Feb 3, 2016
Q1 2016 Becton Dickinson and Co Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 27, 2016
Becton Dickinson and Co Annual Shareholders Meeting (Estimated) - 1:00PM EST - Add to calendar
Nov 17, 2015
Becton Dickinson and Co at Stifel Healthcare Conference - Webcast
Nov 4, 2015
Q4 2015 Becton, Dickinson and Co Earnings Release
Nov 4, 2015
Q4 2015 Becton Dickinson and Co Earnings Call - Webcast
Sep 17, 2015
Becton, Dickinson and Co at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 5.92% 6.76%
Operating margin 9.64% 10.45%
EBITD margin - 23.25%
Return on average assets 2.69% 3.54%
Return on average equity 10.07% 11.38%
Employees 49,517 -
CDP Score - 92 B


1 Becton Dr
United States - Map
+1-201-8476800 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company's Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company's BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Company's BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.

Officers and directors

Vincent A. Forlenza Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Christopher R. Reidy Chief Financial Officer, Executive Vice President - Administration
Age: 57
Bio & Compensation  - Reuters
Alexandre Conroy President, Europe, EMA and the Americas
Age: 51
Bio & Compensation  - Reuters
James Lim President, Greater Asia
Age: 50
Bio & Compensation  - Reuters
Thomas E. Polen Segment President — Medical
Age: 41
Bio & Compensation  - Reuters
Linda M. Tharby Segment President — Life Sciences
Age: 46
Bio & Compensation  - Reuters
William A. Kozy Chief Operating Officer, Executive Vice President
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gary M. Cohen Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Nabil Shabshab Senior Vice President, Chief Marketing Officer
Age: 49
Bio & Compensation  - Reuters
Jeffrey S Sherman Senior Vice President, General Counsel
Age: 59
Bio & Compensation  - Reuters